Rich Pharmaceuticals, Inc.: 10-Q filed 2017-02-13
What Rich Pharmaceuticals, Inc. reported in its quarterly report filed 2017-02-13 (fiscal Q3 2017): 22 published measures, 50 facts as tagged in accession 0001662252-17-000023.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2017-02-13
- Fiscal period
- fiscal Q3 2017
- Accession
- 0001662252-17-000023 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Rich Pharmaceuticals, Inc. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 2,437 | USD | |
| At 2016-03-31 | 6,531 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 3,207,538 | USD | |
| At 2016-03-31 | 2,398,233 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -3,205,101 | USD | |
| At 2016-03-31 | -2,391,702 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -540,450 | USD | 92 |
| 2016-04-01 to 2016-12-31 | -985,332 | USD | 275 |
| 2015-10-01 to 2015-12-31 | -900,723 | USD | 92 |
| 2015-04-01 to 2015-12-31 | -1,857,689 | USD | 275 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-12-31 | -288,931 | USD | 275 |
| 2015-04-01 to 2015-12-31 | -343,012 | USD | 275 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-12-31 | 288,931 | USD | 275 |
| 2015-04-01 to 2015-12-31 | 331,597 | USD | 275 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-12-31 | -1,054 | USD | 275 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | -10,188,773 | USD | |
| At 2016-03-31 | -9,203,440 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 2,437 | USD | |
| At 2016-03-31 | 3,731 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-12-31 | 198,128 | USD | 275 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -208,816 | USD | 92 |
| 2016-04-01 to 2016-12-31 | -607,088 | USD | 275 |
| 2015-10-01 to 2015-12-31 | -298,595 | USD | 92 |
| 2015-04-01 to 2015-12-31 | -859,036 | USD | 275 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 2,800 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | -43,715 | USD | 92 |
| 2016-04-01 to 2016-12-31 | -186,189 | USD | 275 |
| 2015-10-01 to 2015-12-31 | -19,872 | USD | 92 |
| 2015-04-01 to 2015-12-31 | -40,127 | USD | 275 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 3,207,538 | USD | |
| At 2016-03-31 | 2,398,233 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 366,564 | USD | |
| At 2016-03-31 | 1,139,431 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 208,816 | USD | 92 |
| 2016-04-01 to 2016-12-31 | 607,088 | USD | 275 |
| 2015-10-01 to 2015-12-31 | 298,595 | USD | 92 |
| 2015-04-01 to 2015-12-31 | 859,036 | USD | 275 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2015-04-01 to 2015-12-31 | 9,000 | USD | 275 |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 5,670,271 | USD | |
| At 2016-03-31 | 6,589,374 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-12-31 | 896,614 | USD | |
| At 2016-03-31 | 530,150 | USD |
Prepaid expenses and other current assets
Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2016-03-31 | 2,800 | USD |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-10-01 to 2016-12-31 | 431 | USD | 92 |
| 2016-04-01 to 2016-12-31 | 1,293 | USD | 275 |
| 2015-04-01 to 2016-03-31 | 799 | USD | 366 |
| 2015-10-01 to 2015-12-31 | 206 | USD | 92 |
| 2015-04-01 to 2015-12-31 | 443 | USD | 275 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2016-04-01 to 2016-12-31 | 127,133 | USD | 275 |
| 2015-04-01 to 2015-12-31 | 70,247 | USD | 275 |
Inspect the source
- Entity
- Rich Pharmaceuticals, Inc. / CIK 0001504389
- Captured
- SEC response SHA-256
915b548928758b0cd7825b62d7fc36ff2ecd50f0e88985055b0b19ae94428b67
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001504389.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))